Skip to main content

Bryant v. Hoffmann-La Roche, Inc.

Citations

  • 585 S.E.2d 723
  • 262 Ga. App. 401
  • 51 U.C.C. Rep. Serv. 2d (West) 422
  • 2003 Fulton County D. Rep. 2364
  • 2003 Ga. App. LEXIS 945

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

  • no breach of warranty claim by patient who used drug because there was no privity between the manufacturer of drug and patient since patient did not purchase drug directly from manufacturer
  • physical precedent, with one judge urging adoption of a design defect test in the Restatement (Third) of Torts, which test was neither adopted by Congress in the Vaccine Act nor in existence at the time
  • “A claim for negligent failure to warn exists separately from strict liability claims.”
  • “[O]nce a prima facie case for design defect is established, we hold that a pharmaceutical manufacturer will be relieved from strict liability only when it demonstrates that it has met the requirements of Comment k.”
  • where plaintiff did not purchase drug directly from the manufacturer, plaintiff did not fall into class of third-party beneficiaries who could recover for a breach of implied warranty claim, and thus no recovery on this claim was possible

Source: CourtListener parenthetical corpus (CC0).

Judges: Adams, Barnes, Andrews

Read full opinion on CourtListener

Cited by

20 cases in this archive cite this case.

Cites

29 cases in this archive are cited by this case; the 20 most cited are listed.

Sourced from CourtListener / Free Law Project (CC0).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.